Cargando…

Effect of a Dual PPAR α/γ agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia- Randomized double-blind placebo-controlled trial

Saroglitazar is a dual PPAR-α/γ agonist approved for the treatment of diabetic dyslipidemia. In addition to reduction in atherogenic lipids, it may also contribute to improvement in insulin sensitivity through PPAR-α/γ agonism, which remains unexplored. We conducted a randomized, double-blind, place...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jain, Nimisha, Bhansali, Shobhit, Kurpad, Anura V., Hawkins, Meredith, Sharma, Akhilesh, Kaur, Sandeep, Rastogi, Ashu, Bhansali, Anil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6908698/ https://www.ncbi.nlm.nih.gov/pubmed/31831868 http://dx.doi.org/10.1038/s41598-019-55466-3

Ejemplares similares

Effect of Linagliptin and Voglibose on metabolic profile in patients with Type 2 Diabetes: a randomized, double-blind, placebo-controlled trial
por: Parthan, Girish, et al.
Publicado: (2018)

Autologous bone marrow-derived mononuclear cells transplantation in type 2 diabetes mellitus: effect on β-cell function and insulin sensitivity
por: Bhansali, Shobhit, et al.
Publicado: (2017)

SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review
por: Rastogi, Ashu, et al.
Publicado: (2017)

Improved glycemic control amongst people with long-standing diabetes during COVID-19 lockdown: a prospective, observational, nested cohort study
por: Rastogi, Ashu, et al.
Publicado: (2020)

An unusual presentation of a usual disorder: Van Wyk-Grumbach syndrome
por: Rastogi, Ashu, et al.
Publicado: (2011)

Nodular goiter with multiple cystic and solid swellings
por: Rastogi, Ashu, et al.
Publicado: (2012)

Efficacy and safety of rapid escalation of cabergoline in comparison to conventional regimen for macroprolactinoma: A prospective, randomized trial
por: Rastogi, Ashu, et al.
Publicado: (2012)

Glucose-dependent Insulinotropic Polypeptide (GIP) Resistance and β-cell Dysfunction Contribute to Hyperglycaemia in Acromegaly
por: Shekhawat, Vikram Singh, et al.
Publicado: (2019)

Virtual triage and outcomes of diabetic foot complications during Covid-19 pandemic: A retro-prospective, observational cohort study
por: Rastogi, Ashu, et al.
Publicado: (2021)

Diagnostic accuracy of tests for type 2 diabetes and prediabetes: A systematic review and meta-analysis
por: Kaur, Gunjeet, et al.
Publicado: (2020)

Celiac disease: A missed cause of metabolic bone disease
por: Rastogi, Ashu, et al.
Publicado: (2012)

Metformin upregulates mitophagy in patients with T2DM: A randomized placebo‐controlled study
por: Bhansali, Shipra, et al.
Publicado: (2020)

Impact of post-meal and one-time daily exercise in patient with type 2 diabetes mellitus: a randomized crossover study
por: Pahra, Daizy, et al.
Publicado: (2017)

Randomized Placebo Control Study of Metformin in Psoriasis Patients with Metabolic Syndrome (Systemic Treatment Cohort)
por: Singh, Surjit, et al.
Publicado: (2017)

Effect of zoledronic acid on bone mineral density in patients of celiac disease: A prospective, randomized, pilot study
por: Kumar, Mukul, et al.
Publicado: (2013)

Comparative study of clinical features of patients with celiac disease & those with concurrent celiac disease & type 1 diabetes mellitus
por: Bhadada, Sanjay Kumar, et al.
Publicado: (2017)

Long-term foot outcomes following differential abatement of inflammation and osteoclastogenesis for active Charcot neuroarthropathy in diabetes mellitus
por: Das, Liza, et al.
Publicado: (2021)

Efficacy and safety of autologous bone marrow derived hematopoietic stem cell transplantation in patients with type 2 DM: A 15 months follow-up study
por: Bhansali, Anil, et al.
Publicado: (2014)

Validation of bedside methods in evaluation of diabetic peripheral neuropathy
por: Jayaprakash, P., et al.
Publicado: (2011)

Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort)
por: Singh, Surjit, et al.
Publicado: (2016)

Demystifying “Steroid Withdrawal” During Remission in Cushing's Disease: Is Mineralocorticoid Replacement the Answer?
por: Jain, Nimisha, et al.
Publicado: (2019)

Demystifying the Relevance of Size Amongst Macro- and Micro-Corticotropinoma: Experience in 206 Patients
por: Gupta, Rahul, et al.
Publicado: (2022)

Spontaneous diabetic myonecrosis: report of four cases from a tertiary care institute
por: Mukherjee, Soham, et al.
Publicado: (2015)

Effect of mesenchymal stem cells transplantation on glycaemic profile & their localization in streptozotocin induced diabetic Wistar rats
por: Bhansali, Shobhit, et al.
Publicado: (2015)

Authors’ response
por: Bhansali, Shobhit, et al.
Publicado: (2016)

Structure-Based Virtual Screening and Discovery of New PPARδ/γ Dual Agonist and PPARδ and γ Agonists
por: Maltarollo, Vinicius G., et al.
Publicado: (2015)

PPAR-α Agonist Fenofibrate Decreased RANTES Levels in Type 2 Diabetes Patients with Hypertriglyceridemia
por: Feng, Xiaomeng, et al.
Publicado: (2016)

PPARγ Agonists: Blood Pressure and Edema
por: Blazer-Yost, Bonnie L.
Publicado: (2010)

PPARγ Agonists: Emergent Therapy in Endometriosis
por: Vallée, Alexandre, et al.
Publicado: (2021)

PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia
por: Feng, Xiaomeng, et al.
Publicado: (2015)

Scaffold-Based Pan-Agonist Design for the PPARα, PPARβ and PPARγ Receptors
por: Zhang, Li-Song, et al.
Publicado: (2012)

Comparative Gene Expression Profiles Induced by PPARγ and PPARα/γ Agonists in Human Hepatocytes
por: Rogue, Alexandra, et al.
Publicado: (2011)

PPARγ Agonists: Potential as Therapeutics for Neovascular Retinopathies
por: Pershadsingh, Harrihar A., et al.
Publicado: (2008)

The Role of PPARγ in the Transcriptional Control by Agonists and Antagonists
por: Tsukahara, Tamotsu
Publicado: (2012)

PPARγ Agonist Beyond Glucose Lowering Effect
por: Sugawara, Akira, et al.
Publicado: (2011)

Relaxation of human pulmonary arteries by PPARγ agonists
por: Kozłowska, Hanna, et al.
Publicado: (2013)

Biological Rationale for the Use of PPARγ Agonists in Glioblastoma
por: Ellis, Hayley Patricia, et al.
Publicado: (2014)

PPAR-γ Agonists and Their Role in Primary Cicatricial Alopecia
por: Harnchoowong, Sarawin, et al.
Publicado: (2017)

PPARγ and Its Agonists in Chronic Kidney Disease
por: Ma, Yuhua, et al.
Publicado: (2020)

Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPARα Agonist with Moderate PPARγ Agonist Activity in Healthy Human Subjects
por: Jani, Rajendra H., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_dbknas2rcqdp1af1tl48m6sti6